HomeQuestion

How do you approach the timing / feasibility of CD38 re-treatment (daratumumab or isatuximab) in a previously CD38-refractory patient with myeloma?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?

What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/steroids, etc.) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?

Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?

If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?

After the MAJESTEC-3 results, and once approved, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.